These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25369852)

  • 1. A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.
    Kakurai Y; Hirakawa A; Hamada C
    J Biopharm Stat; 2015; 25(5):1065-76. PubMed ID: 25369852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
    Shimamura F; Hamada C; Matsui S; Hirakawa A
    J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding in phase I clinical trials based on toxicity probability intervals.
    Ji Y; Li Y; Nebiyou Bekele B
    Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
    Thall PF; Cook JD; Estey EH
    J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.
    Wages NA; Tait C
    J Biopharm Stat; 2015; 25(5):903-20. PubMed ID: 24904956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying a maximum tolerated contour in two-dimensional dose finding.
    Wages NA
    Stat Med; 2017 Jan; 36(2):242-253. PubMed ID: 26910586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
    Yada S; Hamada C
    Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.
    Hirakawa A; Hamada C; Matsui S
    Stat Med; 2013 Nov; 32(26):4515-25. PubMed ID: 23650098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designs for single- or multiple-agent phase I trials.
    Conaway MR; Dunbar S; Peddada SD
    Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-dimensional search algorithm for dose-finding trials of two agents.
    Lee BL; Fan SK
    J Biopharm Stat; 2012; 22(4):802-18. PubMed ID: 22651116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive phase I/II clinical trials for drug combination assessment in oncology using the outcomes of each cycle.
    Yada S; Hamada C
    Pharm Stat; 2017 Nov; 16(6):433-444. PubMed ID: 28840635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II adaptive design for drug combination oncology trials.
    Wages NA; Conaway MR
    Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designs for phase I trials in ordered groups.
    Conaway MR; Wages NA
    Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
    Potter DM
    Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.
    Wang Z; Zhang J; Xia T; He R; Yan F
    J Biopharm Stat; 2024 Jul; 34(4):582-595. PubMed ID: 37461311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of design specifications in dose-finding trials for combination therapies in oncology.
    Hirakawa A; Sato H; Gosho M
    Pharm Stat; 2016 Nov; 15(6):531-540. PubMed ID: 27539365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.